In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must understand a company's dependence on overseas markets, as this offers a window into the company's earnings stability, its ability to benefit from varied economic cycles and its potential for long-term growth. Participation in global economies acts as a defense against economic difficulties at home and a pathway ...

Investors interested in Medical - Instruments stocks are likely familiar with IQVIA Holdings (IQV) and Waters (WAT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Right now, IQVIA Holdings is sporting a Zacks Rank of #2 (Buy), while Waters has a Zacks Rank of #4 (Sell). This means that IQV's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this ...

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well. IQV is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. With a solid Zacks Rank and top-tier Value and VGM Style Scores, IQV should be on investors' short list. One analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate ...

The reported revenue compares to the Zacks Consensus Estimate of $3.79 billion, representing a surprise of +0.69%. The company delivered an EPS surprise of +2.33%, with the consensus EPS estimate being $2.58. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Backlog: $30.60 million compared to the $30.95 million average estimate based ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35907 _____________________________________________________ ...

Life sciences clinical researcher IQVIA's second-quarter results beat analysts' expectations for revenue and net income. The company also raised its full-year guidance. IQVIA said its technology and analytics products were major growth drivers. IQVIA's stock rose nearly 7% in intraday trading Monday to move into positive territory for the year. Growth Driven by Technology & Analytics Solutions Unit Looking ahead, IQVIA narrowed its full-year revenue guidance to a range of $15.43 billion to $15.53 billion fr ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 5% at constant currency, excluding COVID-related work, with adjusted diluted earnings per share increasing by 8.6% [68][76] - Second quarter revenue grew 2.3% on a reported basis and 3.5% at constant currency, with adjusted EBITDA increasing by 2.7% [95][98] - The company expects full-year revenue between $15,425 million and $15,525 million, with adjusted EBITDA between $3,705 million and $3,765 million [101][102] Business Line Data and Key Metrics Changes - Technology & Analytics Solutions (TAS) revenue was $1,495 million, up 2.7% reported and 3.8% at constant currency, with a growth of 4% when excluding COVID work [96] - R&D Solutions (R&DS) revenue was $2,147 million, up 2.4% reported and 3.3% at constant currency, with a growth of 6% when excluding COVID-related work [96] - Contract Sales & Medical Solutions revenue declined by 2.3% reported but grew by 2.8% at constant currency [96] Market Data and Key Metrics Changes - Emerging biotech funding for Q2 was $22.9 billion, up 32% year-over-year, indicating strong market conditions [74] - The backlog reached a record of $30.6 billion, growing by 7.7% year-over-year, with next 12 months revenue from backlog increasing to $7.8 billion [99][100] - The company noted that large pharma clients are cautious with budgetary spending, impacting pricing negotiations [116] Company Strategy and Development Direction - The company is focusing on mission-critical projects and improving responsiveness to client needs, adapting to the cautious spending environment [9][10] - There is a strong emphasis on AI and machine learning solutions to enhance service offerings and operational efficiency [79][92] - The company aims to continue pursuing acquisitions to boost growth, although high valuations are a challenge [27][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the outlook for the business, citing improved decision-making timelines and a gradual market recovery [70][72] - The company anticipates a stronger performance in the second half of the year, particularly in TAS, with a forecast of 6% to 7% growth [72][101] - Management acknowledged ongoing budgetary constraints from large pharma but noted that mission-critical projects are being prioritized [116] Other Important Information - The company has a rich pipeline for acquisitions but is cautious due to high valuations in the market [27][41] - The company was recognized as a leader in medical affairs and life sciences regulatory operations, enhancing its market position [87] Q&A Session Summary Question: Can you discuss the guidance adjustments? - Management indicated that the adjustments in guidance are minor and reflect a review of business unit forecasts, with no significant changes in overall expectations [110][111] Question: What is the current market environment regarding pricing? - Management noted that large pharma clients are exercising budgetary discipline, making pricing negotiations tougher, but there is an improvement in decision timelines [116][118] Question: How are different segments within TAS performing? - Management reported that the data business remains stable, while other segments have shown mid to high-single-digit growth, particularly in real-world analytics [122]

The IQV stock has gained 5.2% over the past six months, outperforming the 2.9% rally of the industry it belongs to. The Research and Development segment's revenues were $2.2 billion, increasing 2.4% from the year-ago quarter and 3.3% on a constant-currency basis. The figure surpassed our estimate of $2.1 billion. The company exited the quarter with cash and cash equivalents of $1.5 billion compared with $1.4 billion at the end of the preceding quarter. Long-term debt (less current portion) was $12.1 billion ...

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. What's Next for IQVIA? Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the ...

IQVIA Reports Second-Quarter 2024 Results RESEARCH TRIANGLE PARK, N.C. – (BUSINESS WIRE) – July 22, 2024 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2024. Revenue for the second quarter of $3,814 million increased 2.3 percent on a reported basis and 3.5 percent at constant currency, compared to the second quarter ...